

To,

The Manager  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400001

Dear Sir/Madam,

**Sub: Outcome of Board meeting under regulation 30 read Schedule III of SEBI (Listing Obligations and Disclosure requirements) regulations, 2015**

Ref: Sangam Health Care Products Limited (Scrip Code: 531625)

With reference to the subject cited, this is to inform the Exchange that at the Board meeting of Sangam Health Care Products Limited held on Tuesday, the 15<sup>th</sup> day of September at 04.30 P.M. at the registered office of the Company the following were duly considered and approved by the Board:

1. Un-audited financial results for the quarter ended 30.06.2020.
2. Limited Review Report for the quarter ended 30.06.2020

The meeting of the Board of Directors commenced at 04.30 P.M (IST) and concluded at 5.30 P.M (IST)

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,  
For Sangam Health Care Products Limited

*A. Bala Gopal*



A. Bala Gopal  
Managing Director  
(DIN: 01702903)

SANGAM HEALTH CARE PRODUCTS LIMITED					
CIN: L45204TG1984PLC111447					
205,206,AMARCHAND SHARMA COMPLEX S.P. ROAD SECUNDERABAD Hyderabad TG 500002 IN					
Statement of Un-Audited Results for the Quarter ended 30.06.2020					
(Amount in Lakhs)					
S.No.	Particulars	Quarter ended			Year ended
		For the Quarter ended 30.06.2020	For the Quarter ended 31.03.2020	For the Quarter ended 30.06.2019	For the Year ended 31.03.2020
		Un-Audited	Audited	Un-Audited	Audited
I.	Revenue from Operations	306.93	395.82	508.76	2,180.55
II.	Other Income	-	(313.53)	315.31	1.78
<b>III.</b>	<b>Total income (I+II)</b>	<b>306.93</b>	<b>82.29</b>	<b>824.07</b>	<b>2,182.33</b>
<b>IV.</b>	<b>Expenses</b>				
	(a) Cost of Materials consumed	135.83	173.36	259.06	1,024.09
	(b) Purchase of stock-in-trade	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	70.26	(82.20)	(7.73)	(39.29)
	(d) Employee benefits expense	46.03	66.76	129.36	552.44
	(e) Finance Cost	-	-	-	-
	(f) Depreciation and amortisation expense	31.39	11.42	37.57	125.54
	(h) Other expenses	69.58	98.81	126.56	469.50
	<b>Total Expenses</b>	<b>353.09</b>	<b>268.15</b>	<b>544.82</b>	<b>2,132.28</b>
<b>V.</b>	<b>Profit / (Loss) before and exceptional items and Tax ( III-IV)</b>	<b>(46.16)</b>	<b>(185.86)</b>	<b>279.25</b>	<b>50.05</b>
VI.	Exceptional Items	-	(291.54)	-	(291.54)
<b>VII</b>	<b>Profit / (Loss) from before tax (V-VI)</b>	<b>(46.16)</b>	<b>105.68</b>	<b>279.25</b>	<b>341.59</b>
<b>VIII.</b>	<b>Tax expense</b>				
	Current Tax	-	-	-	-
	Deferred Tax	-	63.84	-	(63.84)
<b>IX.</b>	<b>Profit/ (Loss) for the period from Continuing operations (VII-VIII)</b>	<b>(46.16)</b>	<b>41.84</b>	<b>279.25</b>	<b>405.43</b>
X	Profit/ (Loss) from discontinuing operations	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-
<b>XII</b>	<b>Profit/ (Loss) from discontinuing operations after tax</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>XIII</b>	<b>Profit/(loss) for the Period (IX+XII)</b>	<b>(46.16)</b>	<b>41.84</b>	<b>279.25</b>	<b>405.43</b>
<b>XIV</b>	<b>Other Comprehensive Incomes</b>				
<b>A).</b>					
	(i) Items that will not be recycled to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
<b>B).</b>					
	(i) Items that may be reclassified to profit or loss	-	-	-	-
	(ii) Income tax on items that may be reclassified to profit or loss	-	-	-	-
	<b>Total Other Comprehensive Income (A+B)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>XV</b>	<b>Total Comprehensive Income for the period (XIII+XIV)</b>	<b>(46.16)</b>	<b>41.84</b>	<b>279.25</b>	<b>405.43</b>
<b>XVI</b>	<b>Earnings Per Equity Share of face value of Rs.10/- each)(for Continuing operations):</b>				
	1) Basic	(0.31)	0.28	1.88	2.73
	2). Diluted	(0.31)	0.28	1.88	2.73
<b>XVII</b>	<b>Earnings Per Equity Share of face value of Rs.10/- each) (for Discontinuing operations):</b>				
	1) Basic	-	-	-	-
	2). Diluted	-	-	-	-
<b>XVIII</b>	<b>Earnings Per Equity Share of face value of Rs.10/- each) (for Continued and Discontinuing operations):</b>				
	1) Basic	(0.31)	0.28	1.88	2.73
	2). Diluted	(0.31)	0.28	1.88	2.73

*Aravind*



XIX	Paid-up equity share capital (Face Value of Rs. 10/- per share)	1,486.07	1,486.07	1,486.07	1,486.07
	<b>NOTES:</b>				
1	In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013, the above Financial Results have been prepared, reviewed by the Statutory Auditors of Company and recommended by Audit Committee and subsequently approved by Board of Directors of Company at their meeting held on 15th Sep. 2020.				
2	The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).				
3	The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison.				
4	The Company is engaged in "manufacturing and trading of medical products." operating hence there are no separate reportable segments as per Ind AS -108 "Operating Segments"				
	<p><b>For SANGAM HEALTH CARE PRODUCTS LIMITED</b></p> <p><i>A Balayorkel</i></p> <p>BALA GOPAL ADDEPALLI Managing Director DIN : 01712903</p>				
	<p>Station: Hyderabad Date : 15th Sep 2020</p>				





**M M REDDY & CO.,**

Chartered Accountant

Phone : 040-65536097

Fax : 040-23478836

Mobile : 98482 71555

91770 20555

**LIMITED REVIEW REPORT**

To,  
The Board of Directors,  
SANGAM HEALTH CARE PRODUCTS LIMITED

We have reviewed the accompanying statement of Un-audited Financial Results of SANGAM HEALTH CARE PRODUCTS LIMITED for the quarter ended 30<sup>th</sup> June, 2020 attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, as amended.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standard) Rules, 2015 is the responsibility of the company management and has been approved by the Board of Directors of the Company. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the Independent auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ( "Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M M Reddy & Co.,  
Chartered Accountants  
Firm Reg. No: 010371S



M Madhusudhana Reddy  
Partner

Membership No. 213077

UDIN: 20213077AAAAL6801

Place: Hyderabad

Date: 15<sup>th</sup> September, 2020.

